Table 1 Main study outcomes
|  |  | All cases (n = 49) | Optimised dose group (n = 16) |
|---|---|---|---|
SLN detection rate | Vulval | 91Â % | 100Â % |
Cervical | 90Â % | 100Â % | |
Endometrial | 68Â % | 100Â % | |
Total | 78Â % | 100Â % | |
Average SLNs detected per woman | Vulval | 1.1 (0–4) | 2 (1–3) |
Cervical | 2.3 (0–4) | 4 (4–4) | |
Endometrial | 0.9 (0–3) | 1.5 (1–3) | |
Total | 1.3 (0–4) | 1.9 (1–4) |